Improved anti-tumor response was also observed in a shorter syngeneic i.p. Ba/F3-HER2 model, where consistent with previous data, IgA outperformed trastuzumab in the absence of CD47-SIRPα signaling. The gene discussed is SIRPA; the disease is neoplasm.